Abstract:OBJECTIVE:To investigate the effect of small interfering RNA (siRNA) targeting human vascular endothelial growth factor (hVEGF) on A549 cell growth in nude mice and angiogenesis on chorioallantoic membrane (CAM) assay.METHODS:Three pairs of hVEGF siRNA-plasmid and non-silencing-plasmid were constructed, and transfected into A549 cells through lipofectamine 2000, respectively. The most effective pair of hVEGF siRNA-plasmid was selected by ELISA and real-time RT-PCR. A549 cells transfected with selected hVEGF siRNA- plasmid, A549 cells transfected with non-silencing-plasmid and A549 cells without transfection were inoculated into nude mice, respectively. Chick embryos were randomly divided into four groups and CAM was treated by different solutions for 48 h: culture media DMEM as negative control group,un-transfected A549 cell culture supernatants as positive control group, hVEGF siRNA A549 cell culture supernatants as hVEGF siRNA group and nonsilencing siRNA A549 cell culture supernatants as non-silencing siRNA group. The CAMs were harvested on d12 for microscopic assays.RESULT:Compared with control group, hVEGF siRNA-plasmid induced 48% reduction in hVEGF secretion by A549 cells accompanied by 70% reduction in hVEGF mRNA. Compared with non-silencing siRNA group, the mean tumor volume of murine xenograft was reduced by 58% in hVEGF siRNA group; time for xenografts growing to 50 mm(3)was delayed by 5.4 d. hVEGF contents in xenograft were reduced by 54%; but mean doubling time of tumors and the growth rate of tumors were not significantly reduced. In CAM assays, hVEGF content was zero in negative group, and in hVEGF siRNA group that was 40%-44% of non-silencing siRNA group or positive group; vessels branch points of CAM in hVEGF siRNA group or non-silencing siRNA group or positive group were increased by 45%-55% compared with negative group; total vessel length of CAM in hVEGF siRNA group was increased by 53% compared with negative group, while in non-silencing siRNA group or positive group that was increased by 97% or 99%. Compared with negative control group, the proliferation of microvessels was increased when cell culture supernatant with hVEGF was added in hVEGF siRNA group, significant proliferated vessels were observed in non-silencing siRNA group or positive group.CONCLUSION:A plasmid-mediated hVEGF siRNA has been constructed and verified, which can effectively downregulate the expression of hVEGF in human A549 cells, resulting in the inhibition of angiogenesis. hVEGF siRNA can delay initial growth of A549 tumor xenograft but not reduce the growth rate.

293. Sustained Expression of Kringle 1 Domain of Human Hepatocyte Growth Factor (HGFK1) Effectively Inhibits Angiogenesis, Growth and Metastasis of Hepatocellular Carcinoma

Study of Adeno-Associated Virus Carrying the HGFK1 Gene(aav-Hgfk1) in Treating Rat Hepatocellular Carcinoma

A Novel and Effective Hepatocyte Growth Factor Kringle 1 Domain and P53 Cocktail Viral Gene Therapy for the Treatment of Hepatocellular Carcinoma

Effect of Adenovirus-Associated Virus Carrying Kringle 1 Domain of Hepatocyte Growth Factor Gene on the Growth of Human Prostatic Carcinoma Xenograft in Nude Mouse Bone

HGFK1 Enhances the Anti-Tumor Effects of Angiogenesis Inhibitors via Inhibition of CD90+ CSCs in Hepatocellular Carcinoma

Inhibition of Human Hepatocellular Carcinoma Tumor Angiogenesis by Sirna Silencing of VEGF Via Hepatic Artery Perfusion.

A Novel Antiangiogenic Peptide Derived From Hepatocyte Growth Factor Inhibits Neovascularization In Vitro And In Vivo

Hvegf Sirna Inhibits Initial Growth of A549 Tumor Cells in Nude Mice and Angiogenesis on CAM Assay

Suppression Of Angiogenesis And Tumor Growth In Vitro And In Vivo Using An Anti-Angiopoietin-2 Single-Chain Antibody

HGFK1 inhibits bone metastasis in breast cancer through the TAK1/p38 MAPK signaling pathway

A Small Interfering RNA Targeting Vascular Endothelial Growth Factor Efficiently Inhibits Growth of VX2 Cells and VX2 Tumor Model of Hepatocellular Carcinoma in Rabbit by Transarterial Embolization-Mediated Sirna Delivery.

Cell-Specific Expression of Artificial Micrornas Targeting Essential Genes Exhibit Potent Antitumor Effect on Hepatocellular Carcinoma Cells

Long-Term Expression of Angiostatin Suppresses Metastatic Liver Cancer in Mice

Kringle 5 of Human Plasminogen Suppresses Hepatocellular Carcinoma Growth Both in Grafted and Xenografted Mice by Anti-Angiogenic Activity

Hgfk1 is Associated with A Better Prognostis and Reverses Inhibition by Gefitinib in Nsclc Cases

Lowered HGK Expression Inhibits Cell Invasion and Adhesion in Hepatocellular Carcinoma Cell Line HepG2.

Inhibitory Efficacy of Local Angiostatin Expression in Treatment of Human Hepatic Carcinoma Cells

[RNA Interference Targeting Focal Adhesion Kinase Inhibited the Growth of Human Hepatocellular Carcinoma Sk-Hep-1].

Inhibitory Effect of Adeno-Associated Virus-Mediated Gene Transfer of Human Endostatin on Hepatocellular Carcinoma

Gene Therapy Targeting Hepatocellular Carcinoma by A Dual-Regulated Oncolytic Adenovirus Harboring the Focal Adhesion Kinase Shrna

AGK enhances angiogenesis and inhibits apoptosis via activation of the NF-κB signaling pathway in hepatocellular carcinoma.